Literature DB >> 29603827

Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients.

Lucas Alessandro1, José M Pastor Rueda1, Miguel Wilken1, Luis Querol2, Mariano Marrodán1, Julián N Acosta1, Alberto Rivero1, Fabio Barroso1, Mauricio F Farez3,4.   

Abstract

Acute inflammatory demyelinating polyneuropathy (AIDP) and acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) are conditions presenting overlapping clinical features during early stages (first 4 weeks), although the latter may progress after 8 weeks. The aim of this study was to identify predictive factors contributing to their differential diagnosis. Clinical records of adult patients with AIDP or A-CIDP diagnosed at our institution between January 2006 and July 2017 were retrospectively reviewed. Demographic characteristics, clinical manifestations, cerebrospinal-fluid (CSF) findings, treatment and clinical evolution were analyzed. Nerve conduction studies were performed in all patients with at least 12 months follow-up. A total of 91 patients were included (AIDP, n = 77; A-CIDP, n = 14). The median age was 55.5 years in patients with A-CIDP vs 43 years in AIDP (P = .07). The history of diabetes mellitus was more frequent in A-CIDP (29% vs 8%, P = .04). No significant differences between groups were observed with respect to: human immunodeficiency virus (HIV) status, presence of auto-immune disorder or oncologic disease. Cranial, motor and autonomic nerve involvement rates were similar in both groups. Patients in the A-CIDP group showed higher frequency of proprioceptive disturbances (83% vs 28%; P < .001), sensory ataxia (46% vs 16%; P = .01), and the use of combined immunotherapy with corticoids (29% vs 3%; P = .005). There were no significant differences in CSF findings, intensive care unit (ICU) admission, or mortality rates. During the first 8 weeks both entities are practically indistinguishable. Alterations in proprioception could suggest A-CIDP. Searching for markers that allow early differentiation could favor the onset of corticotherapy without delay.
© 2018 Peripheral Nerve Society.

Entities:  

Keywords:  Guillain-Barré Syndrome (GBS); acute inflammatory demyelinating polyneuropathy (AIDP); chronic inflammatory demyelinating polyneuropathy (CIDP); diabetes mellitus

Mesh:

Year:  2018        PMID: 29603827     DOI: 10.1111/jns.12266

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  5 in total

Review 1.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

2.  Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology.

Authors:  Pierre R Bourque; J Brooks; J Warman-Chardon; A Breiner
Journal:  J Neurol       Date:  2019-11-16       Impact factor: 4.849

3.  Monocentric study of 28 cases of chronic inflammatory demyelinating polyneuropathy: first Tunisian study.

Authors:  Malek Mansour; Amine Rachdi; Nesrine Baradai; Amel Kacem; Ines Bedoui; Ridha Mrissa
Journal:  Neurol Sci       Date:  2021-05-04       Impact factor: 3.307

4.  Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy.

Authors:  Luise Appeltshauser; Anna-Michelle Brunder; Annika Heinius; Peter Körtvélyessy; Klaus-Peter Wandinger; Ralf Junker; Carmen Villmann; Claudia Sommer; Frank Leypoldt; Kathrin Doppler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-07-24

5.  Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report.

Authors:  Wenhui Liu; Bo Chen; Yiping Liu; Zhiying Luo; Bao Sun; Fang Ma
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.